<DOC>
	<DOCNO>NCT00428168</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled , multicenter , multinational study . Approximately 78 subject ( 39 per treatment group ) randomize 16 week study . A screening visit use determine subject suitability inclusion trial . Within 7 day screen visit , subject meet inclusion criterion none exclusion criterion randomly assign 1 follow 2 treatment group : - Olanzapine OD plus betahistine 24 mg BID ( 48 mg/day total ) , - Olanzapine OD plus matching placebo BID . Double-blind treatment continue 16 week . During period , olanzapine dosage determine accord discretion treat physician . In addition , 5 study visit ( 2 , 4 , 8 , 12 , 16 week ) take place . Study medication ( betahistine match placebo ) administer BID ( morning together olanzapine evening ) . The primary statistical hypothesis test mean change Baseline Week 16 different treatment placebo group</brief_summary>
	<brief_title>Study Examine Effect Betahistine Body Weight Gain Due Olanzapine Treatment</brief_title>
	<detailed_description />
	<mesh_term>Body Weight</mesh_term>
	<mesh_term>Weight Gain</mesh_term>
	<mesh_term>Betahistine</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>Subject ( legal guardian ) capable willing provide sign write informed consent ; Male female subject 16 45 year age ; Body mass index range 18.5 35 kg/m2 ; Diagnosed schizophrenia , schizoaffective disorder , schizophreniform disorder psychosis disorder otherwise specify ( NOS ) accord DSMIV criterion ; Maximum 6 week cumulative lifetime exposure risperidone , OR maximum 3 week cumulative lifetime exposure antipsychotic medication ; Designated manage physician appropriate treatment olanzapine ; If female : nonlactating , negative blood serum pregnancy test result , plan become pregnant study , childbearing potential ( hysterectomy tubal ligation least 6 month prior randomization postmenopausal 1 year ) ; childbearing potential ( include perimenopausal woman menstrual period within one year ) , must practice willing continue practice appropriate birth control ( implant , injectables , oral contraceptive , intrauterine contraceptive device , sexual abstinence , tubal ligation , vasectomized partner ) entire study duration . Has obesity know endocrine origin ( e.g. , Cushing 's disease , Addison 's disease , hypothalamic tumor ) ; Has medical history ( e.g. , morbid childhood obesity ) and/or physical characteristic ( e.g. , polydactyly ) suggestive genetic obesity ( e.g. , ob/ob genotype ) syndromatic obesity ( e.g. , PraderWilli syndrome , Bardet Biedl syndrome ) ; Previous surgical procedure weight loss ; Has liposuction within 1 year screen plan liposuction study ; Has clinically significant history presence follow condition : Active past history cardiovascular cerebrovascular disease include unstable angina , myocardial infarction , transient ischemic attacks/stroke , clinically significant arrhythmia , congestive heart failure , cardiac valve abnormality ; Type 1 diabetes mellitus ; Type 2 diabetes mellitus treatment metformin monotherapy and/or diet HbA1c &gt; 8 % ; Severe type 2 diabetes history ketoacidosis diabetic ulcer , presence retinopathy , neuropathy , nephropathy ; Renal insufficiency define serum creatinine &gt; =1.5 mg/dL ( 133 µmol/L ) screening ; Malignant disease , basal cell carcinoma , within 5 year screen ; Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &gt; 2 x ULN ; Thyroidstimulating hormone ( TSH ) outside normal range ; Plans surgery ( elective otherwise ) course study ; Has uncontrolled hypertension ( sit blood pressure &gt; 160/95 mmHg screen randomization ) , uncontrolled hyperlipidemia ( triglycerides [ TG ] &gt; =400 mg/dL lowdensity lipoprotein cholesterol [ LDL ] &gt; 160 mg/dL ) , uncontrolled diabetes ( HbA1c &gt; 8 % ) ; Diagnosis asthma ; History peptic ulcer ; History HIV ; Has physical examination electrocardiogram ( ECG ) significant abnormality , judge investigator ; Chronic antihistamine use use antihistamine within 14 day randomization ; History pheochromocytoma Requires treatment follow medication stable treatment regimen minimum 90 day prior screen : Hormone replacement therapy ; Oral contraceptive ; Antihypertensive agent ; Metformin ; Lipidlowering agent ; Thyroid replacement therapy ; Has treat past 60 day , currently treat , expect require undergo treatment follow excluded medication ; All prescription overthecounter agent take purpose weight reduction , include ( limit ) follow anti obesity agent : Prescription drug orlistat ( Xenical ) , sibutramine ( Meridia ) , phentermine ( AdipexP , Celltech , ProFast SA , ProFast SR , Fastin , Oby trim , Zantryl , Teramine , Phentride , Phentercot , Obephen , Obycap ) ; Overthecounter antiobesity agent ( e.g. , herbal supplement alternative remedy Cortislim , Dexatrim , Acutrim ) ; Systemic steroid administer oral , intravenous , intramuscular route ; Drugs directly affect gastrointestinal motility ( e.g. , Reglan® Propulsid® , chronic [ take 10 day within 6month period ] macrolide antibiotic erythromycin new derivative ) ; Antidepressants benzodiazepines unless one follow permit drug : escitalopram ( Cipralex® ) , citalopram ( Celexa® ) , clonazepam ( Clonapam® ) , alprazolam ( Xanax® ) , chlordiazepoxide ( Librium® ) , diazepam ( Valium® ) lorazepam ( Ativan® ) ; Calcitonin ( e.g. , Miacalcin® ) ; Insulin ; Exenatide ( Byeta® ) ; Sulfonylureas ( e.g. , Diamicron® , Amaryl® , Glucotrol® , Micronase® ) ; Meglitinides ( e.g. , Starlix® , Prandin® ) ; Receipt investigational treatment ( drug device ) within 90 day prior screen ; Is immediate family member personnel directly affiliate study investigative site , personally directly affiliate study investigative site .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>Betahistine</keyword>
	<keyword>Weight Gain Control</keyword>
	<keyword>Weight Gain due Olanzapine Treatment</keyword>
	<keyword>Obesity</keyword>
	<keyword>Schizophrenic disorder</keyword>
</DOC>